The new generation of recombinant human hematopoietic cytokines.
In the past year, the most exciting development in the field of hematopoietic growth factors has been the identification of the platelet-inducing factor Mpl ligand. Administration of recombinant Mpl ligand may alleviate the potential for hemorrhagic complications following cancer therapies. Stem cell factor continues to be studied clinically in the mobilization of peripheral blood cells for transplantation.
Amgen Inc, Thousand Oaks, USA.
P
P
Hunt
M
M
Foote
D001709:Biotechnology; D001792:Blood Platelets / Q000187:drug effects; D003001:Cloning, Molecular; D016207:Cytokines / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006410:Hematopoiesis / Q000187:drug effects; D016298:Hematopoietic Cell Growth Factors / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D011994:Recombinant Proteins / Q000235:genetics / Q000302:isolation & purification / Q000627:therapeutic use; D019089:Stem Cell Factor / Q000302:isolation & purification / Q000627:therapeutic use; D013926:Thrombopoietin / Q000302:isolation & purification / Q000627:therapeutic use
D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013926:Thrombopoietin